People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Biotechnology, Pharmaceuticals, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Synlogic, Inc. | — | Biotechnology | Series C | $186.5M | $3.3B | 2015 |
| Checkmate Pharmaceuticals, Inc. | — | Biotechnology | Series C | $185.1M | $3.5B | 2018 |
| Attralus, Inc. | — | Biotechnology | Series D+ | $172.8M | $708.5M | 2021 |
| iPierian, Inc. | — | Pharmaceuticals | Series B | $87.3M | $985.1M | 2009 |
| Tallac Therapeutics, Inc. | — | Pharma | Series C | $61.6M | $2.2B | 2020 |
| Limerick Biopharma Inc | — | Pharmaceuticals | Series B | $52.8M | $16.3M | 2009 |
| Axonis Therapeutics, Inc. | — | Biotechnology | Series C | $46.0M | $365.9M | 2024 |
| NFlection Therapeutics, Inc. | — | Biotechnology | Series B | $44.0M | $43.5M | 2016 |
| Solstice Biologics LLC | — | Pharmaceuticals | Series A | $22.0M | $123.9M | 2012 |
| Alexo Therapeutics Ltd | — | Biotechnology | Series B | $18.0M | $715.3M | 2015 |
| Labrys Biologics, Inc. | — | Pharmaceuticals | Series A | $14.6M | $451.8M | 2012 |
| Insamo Inc. | — | Biotechnology | Series A | $11.8M | $15.6M | 2023 |
| Second Genome, Inc. | — | Biotechnology | Series A | $5.0M | $180.8M | 2011 |
Corey Goodman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Corey Goodman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Corey S. Goodman | 3 | 4 |
| Michael Powell | 2 | 14 |
| Michael Carusi | 2 | 7 |
| Matthew Winkler | 2 | 3 |
| Michael M Powell | 2 | 2 |
| Jaume Pons | 2 | 2 |
| Peter Barrett | 1 | 18 |
| John Walker | 1 | 17 |
| Wende Hutton | 1 | 16 |
| Kristina Burow | 1 | 16 |
| Beth Seidenberg | 1 | 15 |
| Robert Weisskoff | 1 | 12 |
| Edward Mathers | 1 | 12 |
| Ed Mathers | 1 | 11 |
| Chad Waite | 1 | 11 |
| Ketan Patel | 1 | 10 |
| Mark De Souza | 1 | 10 |
| Isaac Cheng | 1 | 9 |
| Ben Auspitz | 1 | 9 |
| Chau Khuong | 1 | 9 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.